Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
   PubMed Web of Science ®Google Scholar
• Primary open-angle glaucoma preferred practice pattern - 2015. American Academy of Ophthalmology; Published 2015 Nov 13 [cited 2018 Mar 8]. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp-2015
   Google Scholar
• Global Data on Visual Impairments 2010. World Health Organization; 2010; [cited 2018 Mar 8]. http://www.who.int/blindness/publications/globaldata/en/
   Google Scholar
• Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538.
   PubMedGoogle Scholar
• Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The baltimore eye survey. JAMA. 1991;266(3):369–374.
   PubMed Web of Science ®Google Scholar
• Gordon MO, Kass MA. What we have learned from the ocular hypertension treatment study. Am J Ophthalmol. 2018 May. DOI:10.1016/j.ajo.2018.02.016
   Web of Science ®Google Scholar
• The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):498–505.
   PubMed Web of Science ®Google Scholar
• Schulzer M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology. 1992 Sep;99(9):1468–1470.
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol Chic Ill 1960. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol Chic Ill 1960. 2002;120(6):701–713. discussion 829-830.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the early manifest glaucoma trial. Curr Opin Ophthalmol. 2004;15(2):102–106.
   PubMedGoogle Scholar
• Leske MC, Hyman L, Hussein M, et al. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1999;127(5):625–626.
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429–440.
   PubMed Web of Science ®Google Scholar
• Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol. 1999;117(5):573–583.
   PubMed Web of Science ®Google Scholar
• Aliancy J, Stamer WD, Wirostko BA. Review of nitric oxide for the treatment of glaucomatous disease. Ophthalmol Ther. 2017;6(2):221–232.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–127.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/Timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69.
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• Waterman H, Evans JR, Gray TA, et al. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013;(4):CD006132. DOI:10.1002/14651858.CD006132.pub3
   PubMed Web of Science ®Google Scholar
• Olthoff CMG, Schouten JSAG, Van De Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112(6):953–961.e7.
   PubMed Web of Science ®Google Scholar
• Blumberg DM, Prager AJ, Liebmann JM, et al. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D. JAMA Ophthalmol. 2015;133(9):985–996.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24(12):1007–1016.
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010;11(6):959–968.
   PubMed Web of Science ®Google Scholar
• Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008;17(8):674–679.
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Webers CAB, Beckers HJM, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010;117(11):2067–2074.e1-6.
   PubMed Web of Science ®Google Scholar
• MIKELAN® LA ophthalmic solution 1%; MIKELAN® LA ophthalmic solution 2%. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2008.
   Google Scholar
• Henness S, Harrison TS, Keating GM. Ocular carteolol. Drugs Aging. 2007;24(6):509–528.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Crider JY, et al. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2001;17(4):305–317.
   PubMed Web of Science ®Google Scholar
• Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol. 1990;109(5):511–517.
   PubMed Web of Science ®Google Scholar
• Floreani M, Froldi G, Cavalli M, et al. Characterization of intrinsic sympathomimetic activity of carteolol in rat cardiovascular preparations. J Pharmacol Sci. 2004;95(1):115–123.
   PubMed Web of Science ®Google Scholar
• Tham Y-C, Lim S-H, Gupta P, et al. Inter-relationship between ocular perfusion pressure, blood pressure, intraocular pressure profiles and primary open-angle glaucoma: the Singapore epidemiology of eye diseases study. Br J Ophthalmol. 2018 January. DOI:10.1136/bjophthalmol-2017-311359
   Web of Science ®Google Scholar
• Mizuki K, Yamazaki Y. Effect of carteolol hydrochloride on ocular blood flow dynamics in normal human eyes. Jpn J Ophthalmol. 2000;44(5):570.
   PubMedGoogle Scholar
• Tamaki Y, Araie M, Tomita K, et al. Effect of topical carteolol on tissue circulation in the optic nerve head. Jpn J Ophthalmol. 1998;42(1):27–32.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Azuma I, Araie M, et al. Effect of continuous intravenous infusion of carteolol chloride on tissue blood flow in rabbit optic nerve head. Jpn J Ophthalmol. 1999;43(6):490–494.
   PubMed Web of Science ®Google Scholar
• Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89(10):1293–1297.
   PubMed Web of Science ®Google Scholar
• Lübeck P, Orgül S, Gugleta K, et al. Effect of timolol on anterior optic nerve blood flow in patients with primary open-angle glaucoma as assessed by the Heidelberg retina flowmeter. J Glaucoma. 2001;10(1):13–17.
   PubMed Web of Science ®Google Scholar
• Netland PA, Schwartz B, Feke GT, et al. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution. J Glaucoma. 1999;8(3):164–171.
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131(6):722–728.
   PubMed Web of Science ®Google Scholar
• Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(5):790–795.e4.
   PubMed Web of Science ®Google Scholar
• Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67(2):179–191.
   PubMed Web of Science ®Google Scholar
• Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol Chic Ill 1960. 1999;117(6):794–801.
   PubMedGoogle Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(SUPPL1):S107–S120.
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36(12):2461–2465.
   PubMed Web of Science ®Google Scholar
• Fujio N, Kusumoto N, Odomi M. Ocular distribution of carteolol after single and repeated ocular instillation in pigmented rabbits. Acta Ophthalmol (Copenh). 1994;72(6):688–693.
   PubMed Web of Science ®Google Scholar
• Renard P, Kovalski JL, Cochereau I, et al. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(12):1221–1227.
   PubMed Web of Science ®Google Scholar
• Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91(11):1361–1363.
   PubMed Web of Science ®Google Scholar
• Amemiya M, Tabei K, Furuya H, et al. Pharmacokinetics of carteolol in patients with impaired renal function. Eur J Clin Pharmacol. 1992;43(4):417–421.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Nakamura K, Matsuki S, et al. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity. J Clin Pharmacol. 2002;42(9):1020–1026.
   PubMed Web of Science ®Google Scholar
• Kawase K, Yamamoto T, Muramatsu T, et al. [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study–investigation of the effectiveness, safety and plasma concentration]. Nippon Ganka Gakkai Zasshi. 2010;114(11):976–982.
   PubMedGoogle Scholar
• Xalatan (Latanoprost) ophthalmic solution: package insert for the 2.5 ML fill. FDA; 2011. [cited 2018 Aug 31]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=201006
   Google Scholar
• MIKELUNA Combination ophthalmic solution. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2018. Available from: http://www.info.pmda.go.jp/downfiles/ph/PDF/180078_1319823Q1026_1_04.pdf
   Google Scholar
• Yamamoto T, Ikegami T, Ishikawa Y, et al. Randomized, controlled, phase 3 trials of carteolol/latanoprost fixed combination in primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2016;171:35–46.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Shields MB, Allen RC, et al. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1991;229(3):258–261.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006;15(4):341–345.
   PubMed Web of Science ®Google Scholar
• Haneda M, Shirato S, Maruyama K, et al. Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma. Jpn J Ophthalmol. 2006;50(1):33–37.
   PubMed Web of Science ®Google Scholar
• Kitazawa Y, Group KS. Phase III double-blind study of latanoprost/timolol combination (KP2035) in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Clin Ophthalmol. 2009;63(5):807–815.
   Google Scholar
• Takmaz T, Aşik S, Kürkçüoğlu P, et al. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol. 2008;18(1):60–65.
   PubMed Web of Science ®Google Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268.
   PubMed Web of Science ®Google Scholar
• Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77(6):668–672.
   PubMedGoogle Scholar
• Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol Chic Ill 1960. 2005;123(2):186–192.
   PubMedGoogle Scholar
• Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316–323.
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian latanoprost study group. Ophthalmology. 1995;102(12):1743–1752.
   PubMed Web of Science ®Google Scholar
• Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension a 12-week study. Arch Ophthalmol Chic Ill 1960. 1996;114(8):929–932.
   PubMedGoogle Scholar
• Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension the Latanoprost study group. Ophthalmology. 1996;103(1):126–137.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied [beta]-blockers in glaucoma therapy [Editorial]. Curr Opin Ophthalmol. 1997;8(2):55–58.
   PubMedGoogle Scholar
• Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol. 1993;9(4):373–384.
   PubMedGoogle Scholar
• Diggory P, Cassels-Brown A, Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Ageing. 1996;25(6):424–428.
   PubMed Web of Science ®Google Scholar
• Hugues FC, Le Jeunne C, Munera Y, et al. [Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics]. J Fr Ophtalmol. 1987;10(8–9):485–490.
   PubMed Web of Science ®Google Scholar
• Le Jeunne CL, Hugues FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol. 1989;29(2):97–101.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Dubiner HB, Mundorf TK, et al. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol. 1999;127(2):142–147.
   PubMed Web of Science ®Google Scholar
• Putterman GJ, Davidson J, Albert J. Lack of metabolism of timolol by ocular tissues. J Ocul Pharmacol. 1985;1(3):287–296.
   PubMedGoogle Scholar
• Razeghinejad MR, Tania Tai TY, Fudemberg SJ, et al. Pregnancy and glaucoma. Surv Ophthalmol. 2011;56(4):324–335.
   PubMed Web of Science ®Google Scholar
• OCUPRESS- carteolol hydrochloride solution : drug label information. National Institute of Health; 2006 [cited 2018 Mar 25]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f82e53e-d6db-432f-af68-9de88d1b1720
   Google Scholar
• Salamalekis E, Kassanos D, Hassiakos D, et al. Intra/extra-amniotic administration of prostaglandin F2a in fetal death, missed and therapeutic abortions. Clin Exp Obstet Gynecol. 1990;17(1):17–21.
   PubMedGoogle Scholar
• Lustgarten JS, Podos SM. Topical. Timolol and the nursing mother. Arch Ophthalmol. 1983;101(9): 1381–1382.
   PubMedGoogle Scholar
• Madadi P, Koren G, Freeman DJ, et al. Timolol concentrations in breast milk of a woman treated for glaucoma: calculation of neonatal exposure. J Glaucoma. 2008;17(4):329–331.
   PubMed Web of Science ®Google Scholar
• Maeda-Chubachi T, Chi-Burris K, Simons BD, et al. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study. Ophthalmology. 2011;118(10):2014–2021.
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 1999;3(1):33–39.
   Web of Science ®Google Scholar
• Black AC, Jones S, Yanovitch TL, et al. Latanoprost in pediatric glaucoma—pediatric exposure over a decade. J Am Assoc Pediatr Ophthalmol Strabismus. 2009;13(6):558–562.
   Web of Science ®Google Scholar
• Nguyen QH, Earl M. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2009;25(6):541–544.
   PubMed Web of Science ®Google Scholar